Articles
2011 Review and Outlook for Biotechnology in 2012
Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
2012 Preview: Cancer Immunotherapy Catalysts
2012 represents a period with robust news flow for emerging immuno-oncology companies
Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer
November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.
Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution
Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.
Company Spotlights
Agenus Inc.
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. With our strong platform technologies, multiple product candidates are advancing through the clinic. The most suitable patient populations to benefit from our novel vaccine approach have been defined. View the company’s fact sheet (PDF)
Opinion Editorials
Bear Market Advice and Perspectives
Our management and strategy consulting firm was founded in November 2008, which was clearly a difficult period for the U.S. economy and a year that many investors would like to forget. The Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971. [...]
Innovative Science Briefs
New generation of medicines targeting G-protein coupled receptors (GPCRs)
Heterotrimeric G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors (1) and play a critical role in transmitting signals from outside to inside a cell. GPCRs role in cell physiology and pathophysiology is well documented as nearly all physiological functions are dependent on GCPR signaling (1,2). The activation of a GPCR is [...]
Follow MD Becker Partners